

Monthly Market Commentary

January 2026



dodd&co

doddwealthcare.co.uk

Wealthcare

International Equities Strongest Year in Nearly a Decade

Global equities ended 2025 near all-time highs, driven by earnings strength despite persistent political and macro uncertainty. The outperformance of non-U.S. equities and the AI investment narrative remained focal points in December, though with growing complexity beneath the surface.

AI leaders Oracle and Broadcom posted strong results but suffered share price declines as investors questioned capital expenditure and the sustainability of revenue growth. Investors are increasingly differentiating between AI companies rather than buying the sector indiscriminately. The enthusiasm that propelled valuations to three-year highs now faces scrutiny over returns on AI-related investments.

The US Federal Reserve cut policy rates by 25 basis points to 3.75%, its third consecutive reduction. Chair Powell adopted a cautious stance towards further easing, however. Delayed macro data in the US show a slowing labour market, with unemployment rising to 4.6%, falling inflationary pressure, as core CPI is at its lowest since early 2021, and weakness in manufacturing. Payroll growth stalled, with job losses in three of the last six months. Despite this, third-quarter GDP expanded 4.3%, its strongest pace in two years. This contrast makes monetary policy difficult, and we need to be mindful of this in our asset allocation decisions.

UK GDP contracted 0.1% in October, marking a second consecutive monthly decline. Consumer weakness compounded disinflationary pressures, with CPI easing to 3.2%. The Bank of England cut rates by 25 basis points in a narrow 5-4 vote but signalled future reductions would be "closer calls". Business activity showed modest recovery following the Autumn Budget, with the composite PMI improving to 52.1.

The ECB held rates steady despite modest upgrades to growth and inflation forecasts for 2026. The Bank of Japan proceeded with normalisation, lifting rates to 0.75%. Long-dated yields climbed across developed markets despite widespread easing. This reflects persistent fiscal pressures complicating the transition to neutral policy.

The macro picture is one of near-term weakness, though market participants remain hopeful that reacceleration of global growth is achievable in the second half of 2026. This optimism underpins current positioning but leaves a limited margin for disappointment given elevated valuations and compressed credit spreads.

Commodities presented a mixed picture. Gold rose 1%, capping a 54% gain over the year. Copper rallied 8% on AI infrastructure investment themes. This stands in stark contrast to oil, which posted its worst year since the pandemic. Brent fell 24% (£ terms) over the year amid a persistent supply glut. Even the unexpected capture of Venezuelan President Nicolás Maduro by U.S. forces on January 3rd failed to push energy prices materially higher.

The historic linkage of geopolitical unrest to markets has been rendered largely ineffectual through the lack of energy price pass-through. This phenomenon persisted throughout 2025, with geopolitical developments and market performance notably diverging. The implications for portfolio construction are significant as some hedges against geopolitical risk have proven less effective.

As we exit 2025, several factors support risk assets. Earnings growth is accelerating from high single digits to low double digits year-over-year. Policy rates are falling, which is supportive for both bonds and equities. Corporate balance sheets remain strong. These fundamentals underpin current valuations despite stretched multiples. However, we are monitoring economic data carefully and

remain mindful that weakness in manufacturing and consumer spending may worsen in the near term. The next three to six months are expected to deliver uncomfortably slow employment growth. This creates an uncomfortable backdrop for broadening equity participation until clear signs of reacceleration emerge.


Digesting the data – Asset Class Performance

U.S. equities declined 1.14% in December as market leadership rotated from technology mega-caps towards more cyclical industrial and material companies. Small-capitalisation stocks fell 1.04%. Full-year returns reached 9.29%, respectable but trailing international developed markets. Current technical indicators favour large caps over small, suggesting caution about recovery breadth.


UK and European equities delivered December's strongest returns. UK large-caps advanced 2.45%, finishing the year up 25.82%, the strongest performance since the global financial crisis. UK mid-caps rose 2.26%, ending up 12.97%. European indices rose 2.12%, capping a 26.10% gain. Asian equities gained 0.93%, with Korea and Taiwan recovering strongly from November weakness.

Fixed income showed sector bifurcation. Government bonds posted negative returns as yields rose. Credit sectors outperformed. High-yield debt returned .89%. Tight spreads reflect limited default risk, looser monetary policy, and abundant capital access, but present valuation challenges.

Asset Class Performance: Equities & Alternatives



Asset class performance: Bonds & Cash



Source: Bloomberg, data to 31/12/2025 in GBP

Past performance is not a guide to future performance

For Professional Investor Use only.

The value of investments can go down and you may get back less than invested. This material may include charts displaying financial instruments' past performance as well as estimates and forecasts. Past performance does not predict future returns.

© 2026 Dodd & Co Healthcare All Rights Reserved. The content of this material is a marketing communication, and not independent investment research. As such, the legal and regulatory requirements in relation to independent investment research do not apply to this material and it is not subject to any prohibition on dealing ahead of its dissemination. The material is for general information purposes only (whether or not it states any opinions). It does not consider your personal circumstances or objectives. Nothing in this material is (or should be considered to be) legal, financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by Albemarle Street Partners or Dodd & Co Healthcare that any particular investment, security, transaction, or investment strategy is suitable for any specific person. Although the information set out in this marketing communication is obtained from sources believed to be reliable, Albemarle Street Partners or Dodd & Co Healthcare makes no guarantee as to its accuracy or completeness. Neither Albemarle Street Partners or Dodd & Co Healthcare shall be responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein. Albemarle Street Partners is a trading name of Atlantic House Investments Limited (AHI), which is authorised and regulated by the Financial Conduct Authority ("FCA") FRN 931264. Trading address: 135 Bishopsgate, London, EC2M 3TP. Dodd & Co Healthcare is a trading style of DW 2020 Ltd. DW 2020 is authorised and regulated by the Financial Conduct Authority FRN 921450.